The (cell) matrix reloaded

September 09, 2005

A world-class research facility investigating diseases such as osteoarthritis, cardiovascular disease and cancer has been awarded a further £3 million to continue its groundbreaking work.

The University of Manchester's Wellcome Trust Centre for Cell-Matrix Research has had its core grant renewed - securing infrastructure funding for the next five years.

The Centre, one of only five such Wellcome Trust-funded facilities in the UK and the only one in its field, is home to 21 independent research groups and a total of 170 scientists.

Established in 1995, the Centre is an interdisciplinary research hub whose long-term aims are to clarify the structure and function of extracellular matrices and cellular adhesion.

"The cell matrix is the material in the body in between the cells," explained Professor Martin Humphries, Associate Dean for Research in the Faculty of Life Sciences and the Centre's Director.

"Only two per cent of our body is made up of cells, the rest is the material that endows elastic tissue, bone tissue, ligaments and tendons with their physical and functional properties - that's what we call the matrix.

"Our research aims to define the contribution of cell interactions with matrices to human diseases, and develop approaches for preventing and treating those diseases.

"For instance, there is currently enormous interest in developing ways to modify stem cells for treating joint diseases and brain diseases such as Alzheimer's, but we believe it is critical to give those cells the right environment in which to live.

"Since cells are closely integrated with their surrounding matrix, when regenerating tissues it is logical to provide cells with the correct niche to help them develop in the right way. That's where our research into the cell matrix comes in."

"The work done here impinges on virtually all human diseases, although we have specific interests in cancer, vascular disease and osteoarthritis.

"In cancer, we are looking at the role adhesion plays in regulating tumour spread, while with osteoarthritis we are looking to replace damaged cartilage.

"The research where we're closest to clinical trials, perhaps as soon as next year, is vascular engineering where we want to replace vessels affected by vascular disease."

The Centre, which is based in the new, state-of-the-art Michael Smith Building, boasts one of the world's best collection of scientists in this field; the grant, says Professor Humphries, will help facilitate their pioneering work for a further five years.

"Securing this core funding for a third time is a major accomplishment, and it will allow us to secure new equipment and to cover the salaries of key support staff," he said.

"The core award helps provide the infrastructure necessary to carry out all of our specific project research. These projects are supported by £30 million worth of research grants, two-thirds of which are funded by the Wellcome Trust."
-end-
Notes to editors:

The Wellcome Trust Centre for Cell-Matrix Research was established with an initial Wellcome Trust grant of £2.2 million. This was reviewed in 2000 when a further grant of £3.8 million was awarded. This latest £3.1 million grant is a result of a successful second review carried out on 12 May, 2005.

The Centre is part of the University's Faculty of Life Sciences, one of the largest and most successful unified research and teaching organisations of its kind in Europe with more than 1,000 researchers, 1,500 undergraduate students and an annual budget of more than £100 million.

In January 2004, the Centre moved to the new Michael Smith Building, named after a former graduate of the University and 1993 Nobel Laureate in Chemistry. This building, which was funded in part by a £15 million JIF grant from the Wellcome Trust and the UK Government, provides outstanding laboratory accommodation for the Centre and facilitates access to a wide range of core equipment facilities, including mass spectrometry, X-ray crystallography and fluorescence microscopy. The Centre occupies about 25 per cent of the total floor space of the building.

There are currently 21 independent investigators within the Centre, with expertise ranging from structure determination to whole organism genetics, from molecular biophysics to molecular imaging in living cells. Currently, the Centre houses 170 researchers, including 50 postgraduate research students.

Research into osteoarthritis at the University can be traced back to 1953 with the appointment of Britain's first professor of rheumatology, Jonas Kellgren.

The University of Manchester, created from the merger of The Victoria University of Manchester and UMIST in October 2004, is the UK's largest university with 9,000 staff and 28,802 full-time-equivalent students and an annual income of almost £500 million.

For further information contact:

Aeron Haworth
Press Office
Faculty of Life Sciences
The University of Manchester
Tel: +44 (0)161 275 8383
Mob: +44 (0)7717 881 563
Email: aeron.haworth@manchester.ac.uk

University of Manchester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.